The news isn't too surprising. Shkreli had just taken over as CEO this past November in a last-ditch effort to save the floundering company, but was fired this month after his arrest for allegedly misappropriating funds at previous jobs. Shkreli's money-raising tactics at KaloBios were the same ones he used as CEO of Turing Pharmaceuticals: obtain the license for a standard treatment and jack up the price. Most notably, he did this with Daraprim, an anti-parasitic drug whose cost surged from $13.50 to $750 per pill under Shkreli's reign.
At this point, Shkreli's employment history is looking a little shoddy. In 2014, he was fired from Retrophin, a biotech firm he founded, for "stock trading irregularities," Fast Company reports.